Drugs / Epacadostat
Trials 58 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03277352 Background | Nov 2017 → Jul 2020 | metastatic malignant neoplasm | Incyte Corporation | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01685255 Comparator | Aug 2012 → Oct 2014 | ovarian carcinoma | Incyte Corporation | Terminated | No outcome recorded |
Press releases naming this drug 21 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-04-06 | Incyte Corporation | Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA® (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma incyte.com ↗ |
| 2017-09-09 | Incyte Corporation | Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma incyte.com ↗ |
| 2017-09-09 | Incyte Corporation | Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma incyte.com ↗ |
| 2017-08-30 | Incyte Corporation | New Data for Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Demonstrate Durable Responses in Patients with Advanced Melanoma incyte.com ↗ |
| 2017-06-05 | Incyte Corporation | Updated Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (Pembrolizumab) Demonstrate Clinical Activity across Multiple Tumor Types incyte.com ↗ |
| 2017-06-05 | Incyte Corporation | Clinical Trial Data for Combination of Epacadostat and Opdivo® (nivolumab) Demonstrate Durable Clinical Responses in Patients with Melanoma and Head and Neck Cancer incyte.com ↗ |
| 2017-06-03 | Incyte Corporation | Combination of Incyte’s Epacadostat plus Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Activity in Clinical Trial of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) incyte.com ↗ |
| 2017-06-03 | Incyte Corporation | Combination of Epacadostat plus Keytruda® (pembrolizumab) Demonstrates Activity in Clinical Trial of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) incyte.com ↗ |
| 2017-05-17 | Incyte Corporation | New Data for Presentation at ASCO 2017 Reinforce Clinical Profile of Epacadostat in Combination with Keytruda® (pembrolizumab) incyte.com ↗ |
| 2017-05-17 | Incyte Corporation | First Data from Combination of Epacadostat with Opdivo® (nivolumab) Will Be Highlighted at ASCO 2017 incyte.com ↗ |
| 2017-04-02 | Incyte Corporation | Bristol-Myers Squibb and Incyte to Advance the Combination of Opdivo (nivolumab) and Epacadostat into First-line Registrational Trials incyte.com ↗ |
| 2017-03-31 | Incyte Corporation | Incyte and Merck Provide Additional Details on Previously Announced Collaboration Investigating Epacadostat and KEYTRUDA® (pembrolizumab) incyte.com ↗ |
| 2017-01-09 | Incyte Corporation | Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA® (pembrolizumab) incyte.com ↗ |
| 2016-10-07 | Incyte Corporation | Additional Phase 1 Data from ECHO-202 Reinforce Durability of Response in Patients with Treatment-naive Advanced or Metastatic Melanoma Treated with Epacadostat in Combination with Keytruda® (pembrolizumab) incyte.com ↗ |
| 2016-09-28 | Incyte Corporation | Updated Phase 1 Data Reinforce the Clinical Profile of Epacadostat in Combination with Keytruda® (Pembrolizumab) incyte.com ↗ |
| 2016-07-19 | Incyte Corporation | Updated Data for Epacadostat, Incyte’s Selective IDO1 Inhibitor, Accepted for Presentation at the ESMO Annual Congress 2016 incyte.com ↗ |
| 2015-11-03 | Incyte Corporation | Epacadostat in Combination with Pembrolizumab Demonstrates Promising Clinical Activity in Multiple Advanced Cancers incyte.com ↗ |
| 2015-10-13 | Incyte Corporation | Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda® (pembrolizumab) as First-line Treatment for Advanced Melanoma incyte.com ↗ |
| 2015-10-13 | Incyte Corporation | Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda® (pembrolizumab) as First-line Treatment for Advanced Melanoma incyte.com ↗ |
| 2013-06-01 | Incyte Corporation | Incyte Presents Final Results from a Phase I Trial of INCB024360, a Novel Oral Immunotherapy, at ASCO incyte.com ↗ |
| 2012-06-04 | Incyte Corporation | Incyte Presents Results from a Phase I Trial of INCB024360, a Novel Oral Inhibitor of Indoleamine Dioxygenase-1 (IDO1), at ASCO incyte.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 63 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epacadostat | “The open-label, phase 1/2 ECHO-203 study evaluated the safety, tolerability, and efficacy of the IDO1 inhibitor epacadostat in combination with durvalumab, a human anti-PD-L1...” PMID 36309837 ↗ Oct 202253“Patients will receive epacadostat in combination with pembrolizumab.” NCT03325465 ↗ |
| Known as | INCB024360 | “Epacadostat (INCB024360) is an inhibitor of the enzyme indoleamine 2,3-dioxygenase 1 (IDO1) that has shown promise in the treatment of solid tumors and lymphomas in ongoing...” NCT03322384 ↗13“INCB024360 (Epacadostat) is an IDO1 inhibitor under investigation in combination with different immunotherapies in treatment of various malignancies.” NCT03493945 ↗ “A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)” NCT02318277 ↗ “Phase II Study of Epacadostat (INCB024360) in Combination With Pembrolizumab in Patients With Locally Advanced/Metastatic Sarcoma” NCT03414229 ↗ “Oral Epacadostat (INCB024360) (50, 100, or 300 mg twice per day,on days 1-21 of each cycle, every 21 days)” NCT03182894 ↗ “Epacadostat (INCB024360) is an Inhibitor of Indoleamine 2,3- dioxygenase 1 (IDO1).” NCT03491579 ↗ “Epacadostat (INCB024360) is an Inhibitor of Indoleamine 2,3- dioxygenase 1 (IDO1).” NCT03444649 ↗ “Drug: Epacadostat (INCB024360)” NCT02785250 ↗ |
| Known as | previously INCB24360 | “previously INCB24360” NCT03832673 ↗ |
| Action | Inhibit | “Epacadostat is a potent inhibitor of the immunosuppressive indoleamine 2,3-dioxygenase 1 (IDO1) enzyme.” PMID 30894212 ↗ Mar 2019 |
| Modality | Small molecule | — CHEMBL3545369 ↗ |
| Route | Oral | “Patients received oral epacadostat (25, 50, 100, or 300 mg twice daily [BID]; 75 mg daily [50 mg AM, 25 mg PM]; or 50 mg BID intermittent [2 weeks on/1 week off])” PMID 30894212 ↗ Mar 2019 |
| Target | IDO1 | “Epacadostat is a potent inhibitor of the immunosuppressive indoleamine 2,3-dioxygenase 1 (IDO1) enzyme.” PMID 30894212 ↗ Mar 2019 |